Aug 2026· Medicine· Vol 105· 0 citations· 42 references
Medicine
TL;DR
RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes, but further research is needed to assess long-term efficacy and safety.
Abstract
Background: Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases characterized by immune dysregulation. Despite biologic advancements, many patients experience treatment failure. Risankizumab (RZB), a selective interleukin-23 inhibitor, has emerged as a promising therapy for moderate-to-severe inflammatory bowel diseases. This systematic review evaluates its efficacy, safety, and therapeutic outcomes. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search of PubMed, Embase, Scopus, and ClinicalTrials.gov was conducted to identify studies published up to 2025. Eligible studies included randomized controlled trials, clinical trials, and retrospective observational studies evaluating RZB in adult patients with CD or UC. Primary outcomes included clinical remission, endoscopic response, hospitalization rates, and adverse events. Results: Seventeen studies involving 6602 patients (5627 with CD, 975 with UC) were analyzed. In CD, RZB demonstrated high clinical remission rates, endoscopic healing, and reduced hospitalizations, including in biologic-refractory patients. In UC, it showed significant remission rates and fewer UC-related hospitalizations. RZB was well tolerated, with mostly mild to moderate adverse events such as arthralgia, headache, and nasopharyngitis. Severe adverse events were rare. Conclusion: RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes. It offers a viable option for biologic-refractory patients, but further research is needed to assess long-term efficacy and safety.
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent inflammation of the colon resulting from immune dysregulation. Despite the availability of multiple therapeutic options, a substantial proportion of patients fail to achieve sustained remission or develop loss of re...
Zuzanna Ostrowska, Z. Witkowska, Bartosz Rutka et al.· International Journal of Inn...· 0 citations
IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.
Ylenia Marino, M. Rottura, Claudia Ligresti et al.· Pharmaceuticals· 0 citations
Background & Objective: Tumor necrosis factor-like ligand 1A (TL1A) has been associated with mucosal inflammation, fibrosis, and epithelial barrier dysfunction in inflammatory bowel disease (IBD). Monoclonal antibodies against TL1A have emerged as potential therapies for moderate-to-severe ulcerative colitis (UC) and C...
Hannan Adil, M. Adil, Samawia Kousar et al.· Journal of Saidu Medical Col...· 0 citations
The current evidence supports mechanism-informed rather than biomarker-defined treatment selection, and the mechanistic rationale, comparative clinical evidence, and translational implications of approved and emerging targeted therapies for adult IBD are examined.
C. Pavel, A. Popa, M. Ilie et al.· Journal of Clinical Medicine· 0 citations
BACKGROUND
Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce.
AIM
To evaluate the 12-month effectiveness and safety o...
A. Caballero-Mateos, T. Valdés-Delgado, R. Olmedo Martín et al.· World Journal of Gastroenter...· 1 citation
BACKGROUND AND AIMS
The role of therapeutic drug monitoring (TDM) in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ tro...
Mostafa A. Soliman, Alessandra Saraga, A. Gade et al.· Clinical Gastroenterology an...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.